Caelyx®: phase II studies in ovarian cancer
- 31 December 2001
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 37, 8-14
- https://doi.org/10.1016/s0959-8049(01)00329-x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicinCancer, 2001
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996
- Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacyJournal of Neurosurgery, 1995
- Salvage Chemotherapy for Epithelial Ovarian CarcinomaGynecologic Oncology, 1994
- Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)Journal of Liposome Research, 1994
- Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.Proceedings of the National Academy of Sciences of the United States of America, 1991